223 related articles for article (PubMed ID: 15501526)
21. VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.
Shreeve SM; Sreedharan SP; Hacker MP; Gannon DE; Morgan MJ
Biochem Biophys Res Commun; 2000 Jun; 272(3):922-8. PubMed ID: 10860852
[TBL] [Abstract][Full Text] [Related]
22. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
23. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
Couvineau A; Rouyer-Fessard C; Laburthe M
Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
[TBL] [Abstract][Full Text] [Related]
24. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Dickson L; Aramori I; McCulloch J; Sharkey J; Finlayson K
Neuropharmacology; 2006 Nov; 51(6):1086-98. PubMed ID: 16930633
[TBL] [Abstract][Full Text] [Related]
25. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
Langlet C; Gaspard N; Nachtergael I; Robberecht P; Langer I
Peptides; 2004 Dec; 25(12):2079-86. PubMed ID: 15572195
[TBL] [Abstract][Full Text] [Related]
27. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.
Park CG; Ganguli SC; Pinon DI; Hadac EM; Miller LJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):682-8. PubMed ID: 11046106
[TBL] [Abstract][Full Text] [Related]
28. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
29. Molecular cloning and functional expression of a VIP-specific receptor.
Zhou H; Huang J; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G728-34. PubMed ID: 16959956
[TBL] [Abstract][Full Text] [Related]
30. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
31. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
32. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
33. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
[TBL] [Abstract][Full Text] [Related]
34. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
35. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
36. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
37. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M
J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902
[TBL] [Abstract][Full Text] [Related]
38. Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.
Dérand R; Montoni A; Bulteau-Pignoux L; Janet T; Moreau B; Muller JM; Becq F
Br J Pharmacol; 2004 Feb; 141(4):698-708. PubMed ID: 14744818
[TBL] [Abstract][Full Text] [Related]
39. Properties and regulation of the coupling to adenylate cyclase of secretin receptors stably transfected in Chinese hamster ovary cells.
Vilardaga JP; Ciccarelli E; Dubeaux C; De Neef P; Bollen A; Robberecht P
Mol Pharmacol; 1994 May; 45(5):1022-8. PubMed ID: 8190092
[TBL] [Abstract][Full Text] [Related]
40. The human vasoactive intestinal Peptide/Pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): constitutive activation by mutations at threonine 343.
Gaudin P; Couvineau A; Rouyer-Fessard C; Maoret JJ; Laburthe M
Biochem Biophys Res Commun; 1999 Jan; 254(1):15-20. PubMed ID: 9920725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
